200 related articles for article (PubMed ID: 32282296)
1. Pro-inflammatory Cytokines in Acute Coronary Syndromes.
Mourouzis K; Oikonomou E; Siasos G; Tsalamadris S; Vogiatzi G; Antonopoulos A; Fountoulakis P; Goliopoulou A; Papaioannou S; Tousoulis D
Curr Pharm Des; 2020; 26(36):4624-4647. PubMed ID: 32282296
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
3. Early inflammatory cytokine response: a direct comparison between spontaneous coronary plaque destabilization vs angioplasty induced.
Brunetti ND; Correale M; Pellegrino PL; Munno I; Cuculo A; De Gennaro L; Gaglione A; Di Biase M
Atherosclerosis; 2014 Oct; 236(2):456-60. PubMed ID: 25173071
[TBL] [Abstract][Full Text] [Related]
4. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?
Matusik P; Guzik B; Weber C; Guzik TJ
Thromb Haemost; 2012 Sep; 108(3):443-56. PubMed ID: 22872109
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes.
Baruch A; van Bruggen N; Kim JB; Lehrer-Graiwer JE
Curr Atheroscler Rep; 2013 Jun; 15(6):327. PubMed ID: 23636864
[TBL] [Abstract][Full Text] [Related]
6. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Miyauchi K; Daida H; Morimoto T; Hiro T; Kimura T; Nakagawa Y; Yamagishi M; Ozaki Y; Kadota K; Kimura K; Hirayama A; Kimura K; Hasegawa Y; Uchiyama S; Matsuzaki M;
Circ J; 2012; 76(4):825-32. PubMed ID: 22451449
[TBL] [Abstract][Full Text] [Related]
7. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches.
Tsioufis P; Theofilis P; Tsioufis K; Tousoulis D
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555579
[TBL] [Abstract][Full Text] [Related]
9. Colchicine for the treatment of coronary artery disease.
Aimo A; Pascual-Figal DA; Barison A; Cediel G; Vicente ÁH; Saccaro LF; Emdin M; Bayes-Genis A
Trends Cardiovasc Med; 2021 Nov; 31(8):497-504. PubMed ID: 33096241
[TBL] [Abstract][Full Text] [Related]
10. Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study.
Battes LC; Cheng JM; Oemrawsingh RM; Boersma E; Garcia-Garcia HM; de Boer SP; Buljubasic N; Mieghem NA; Regar E; Geuns RJ; Serruys PW; Akkerhuis KM; Kardys I
Atherosclerosis; 2014 Sep; 236(1):18-24. PubMed ID: 25003948
[TBL] [Abstract][Full Text] [Related]
11. The Role of Colchicine in Acute Coronary Syndromes.
Vaidya K; Martínez G; Patel S
Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of vulnerable plaque on computed tomographic coronary angiography with normal myocardial perfusion image.
Otsuka K; Fukuda S; Tanaka A; Nakanishi K; Taguchi H; Yoshiyama M; Shimada K; Yoshikawa J
Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):332-40. PubMed ID: 24204033
[TBL] [Abstract][Full Text] [Related]
13. Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression.
Ahmadi A; Leipsic J; Blankstein R; Taylor C; Hecht H; Stone GW; Narula J
Circ Res; 2015 Jun; 117(1):99-104. PubMed ID: 26089367
[TBL] [Abstract][Full Text] [Related]
14. [The role of inflammation in the pathophysiology of acute coronary syndromes].
Alber HF; Suessenbacher A; Weidinger F
Wien Klin Wochenschr; 2005 Jul; 117(13-14):445-55. PubMed ID: 16091870
[TBL] [Abstract][Full Text] [Related]
15. [Pathophysiological bases of unstable coronary syndrome].
Waltenberger J
Herz; 2001 Apr; 26 Suppl 1():2-8. PubMed ID: 11349622
[TBL] [Abstract][Full Text] [Related]
16. Update on acute coronary syndromes: the pathologists' view.
Falk E; Nakano M; Bentzon JF; Finn AV; Virmani R
Eur Heart J; 2013 Mar; 34(10):719-28. PubMed ID: 23242196
[TBL] [Abstract][Full Text] [Related]
17. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment.
Crea F; Libby P
Circulation; 2017 Sep; 136(12):1155-1166. PubMed ID: 28923905
[TBL] [Abstract][Full Text] [Related]
18. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study.
Fernandes JL; de Oliveira RTD; Mamoni RL; Coelho OR; Nicolau JC; Blotta MHSL; Serrano CV
Atherosclerosis; 2008 Jan; 196(1):434-442. PubMed ID: 17196208
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarkers and source of inflammation in acute coronary syndromes and percutaneous coronary interventions.
Centurión OA
Cardiovasc Revasc Med; 2016 Mar; 17(2):119-28. PubMed ID: 26905055
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
